DDOG vs MRK: Which Is the Better Buy?

Side-by-side comparison of Datadog, Inc. and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-07-09.
Datadog, Inc. · Technology
$261.09
+45.0% upside to fair value
Grade B High Quality
VS
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D High Quality
QuantHub Verdict
DDOG has more upside to fair value (+45.0%). MRK trades at a lower forward P/E (32.0x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric DDOG MRK
Current Price $261.09 $113.87
Fair Value Estimate $378.58 $100.14
Upside to Fair Value +45.0% -12.1%
Market Cap $92.9B $281.2B
Forward P/E 678.5x 32.0x
EV / EBITDA 410.4x 17.3x
Price / Sales 25.3x 4.3x
Price / FCF 86.1x 19.9x
Revenue Growth YoY +32.2% +4.3%
Gross Margin 79.9% 75.9%
Operating Margin -0.7% 27.6%
Return on Equity 3.8% 17.9%
Dividend Yield 0% 0%
FCF Yield 1.16% 5.02%
Analyst Consensus Strong Buy Hold
Investment Thesis
DDOG — Datadog, Inc.
Datadog, Inc. is a leading provider of cloud-scale monitoring and analytics software for developers, IT operations teams, and business users in the technology sector. The company exhibits strong business quality with a durable competitive moat supported by high gross margins of 79.9% and rapid revenue growth of 32.2% in the most recent quarter. Despite this, the stock trades at a very high valuat…
MRK — Merck & Co., Inc.
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Accumulation Zones
Metric DDOG MRK
Zone Low $283.94 $75.11
Zone High $321.79 $85.12
In Buy Zone? Yes No
← DDOG Research    MRK Research →    All Research